Table 3. Hematological parameters of the study participants throughout the study .
| OEA (n=37) | Placebo (n=37) | MD (95% CI), P | |
| WBC (103/µL) | |||
| Baseline | 7.06 (1.44) | 6.89 (1.29) | 0.17 (-0.46, 0.80), 0.601b |
| End | 7.04 (1.35) | 6.96 (1.51) | 0.37 (-0.40, 1.14), 0.343 c |
| MD (95% CI), Pa | -0.02 (-0.45, 0.40), 0.910 | 0.06 (-0.28, 0.42), 0.698 | |
| Hb (g/dL) | |||
| Baseline | 14.31 (1.57) | 14.50 (1.93) | 0.18 (-1.00, 0.63), 0.656b |
| End | 15.39 (1.60) | 15.54 (1.98) | 0.11 (-0.72, 0.48), 0.700c |
| MD (95% CI), Pa | 1.08 (0.84, 1.32), <0.001 | 1.04 (0.74, 1.35), <0.001 | |
| RBC (106/µL) | |||
| Baseline | 5.03 (0.43) | 5.13 (0.44) | 0.10 (-0.31, 0.09), 0.095b |
| End | 5.14 (0.51) | 5.12 (0.45) | 0.12 (-0.06, 0.31), 0.188c |
| MD (95% CI), Pa | 0.11 (0.03, 0.18), 0.004 | -0.29 (-1.25, 0.65), 0.532 | |
| HCT (%) | |||
| Baseline | 43.30 (4.10) | 44.06 (4.89) | 0.75 (-2.85, 1.33), 0.472b |
| End | 44.77 (4.39) | 44.92 (4.96) | 0.85 (-2.39, 0.67), 0.267c |
| MD (95% CI), Pa | 1.46 (0.85, 2.08), <0.001 | 0.86 (0.09, 1.62), 0.028 | |
| MCV (FL) | |||
| Baseline | 85.04 (9.61) | 86.15 (6.71) | 0.75 (-2.85, 1.33), 0.472b |
| End | 86.95 (10.05) | 88.14 (5.39) | 0.04 (-1.73, 1.64), 0.955c |
| MD (95% CI), Pf | 1.91 (1.22, 2.58), <0.001 | 1.98 (1.09, 2.88), <0.001 | |
| MCH (pg) | |||
| Baseline | 28.65 (1.69) | 33.02 (2.91) | 0.17 (-0.92, 1.27), 0.752b |
| End | 34.18 (1.67) | 34.13 (6.04) | 0.65 (-4.04, 2.73), 0.698c |
| MD (95% CI), Pf | 1.66 (1.30, 2.01), <0.001 | 3.18 (0.62, 5.72), 0.016 | |
| MCHC (g/dL) | |||
| Baseline | 32.95 (1.65) | 33.01 (1.09) | 0.06 (-0.71, 0.57), 0.837b |
| End | 34.18 (1.82) | 34.13 (2.29) | 0.47 (-1.63, 0.68), 0.417c |
| MD (95% CI), P | 0.29 (0.96, 1.48), <0.001 | 1.12 (0.46, 1.76), 0.001 | |
| RDW (%) | |||
| Baseline | 12.11 (0.67) | 12.41 (1.15) | 0.29 (-0.73, 0.14), 0.182b |
| End | 11.63 (0.80) | 12.08 (0.77) | 0.28 (-0.56, -0.003), 0.041c |
| MD (95% CI), P | 0.48 (-0.70, -0.25), <0.001 | 0.32 (-0.58, -0.72), 0.014 | |
| PLT (103/ µL) | |||
| Baseline | 270.35 (50.88) | 258.02 (54.21) | 12.32 (-12.04, 36.69), 0.317b |
| End | 255.51 (49.90) | 242.64 (55.59) | 0.74 (-14.19, 15.68), 0.921c |
| MD (95% CI), P | 14.83 (-19.61, -10.06), <0.001 | 15.37 (-25.27, -5.48), 0.003 | |
| MPV (FL) | |||
| Baseline | 8.02 (0.86) | 7.79 (0.47) | 0.23 (-0.09, 0.55), 0.157b |
| End | 8.06 (0.81) | 7.99 (0.49) | 0.07 (-0.16, 0.31), 0.548c |
| MD (95% CI), P | 0.04 (-0.07, 0.16), 0.456 | 0.19 (-0.08, 0.31), 0.141 | |
| PDW | |||
| Baseline | 16.78 (0.60) | 16.85 (0.65) | 0.06 (-0.36, 0.22), 0.642b |
| End | 16.63 (1.59) | 16.94 (0.77) | -0.52 (-1.43, 0.38), 0.255c |
| MD (95% CI), P | 0.16 (-0.33, -0.007), 0.041 | 0.32 (-0.58, -0.07), 0.014 |
OEA, Oleoylethanolamide; WBC, White blood cell; Hb, Hemoglobin; RBC, Red blood cell; HCT, Hematocrit; MCV, Mean corpuscular volume; MCH, Mean corpuscular
hemoglobin; MCHC, Mean corpuscular hemoglobin concentration; RDW, Red blood cell distribution width; PLT, Platelet; MPV, Mean platelet volume; PDW, Platelet distribution width.
Mean (SD) and Mean Difference (95% CI) are presented for data.
a Paired samples t test.
b Independent samples t test.
c ANCOVA test, adjusted for baseline values, age, changes in physical activity, energy intake, and BMI.